Title:
A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
Phase:
II
Contact:
Stephanie Cordeiro de Lima / Kontaktperson
Clinical Investigator:
PD Dr. med. Stefanie Zschäbitz
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT06534983
EudraCT-Number:
Keine Registernummer angegeben.
